Skip to content
drillr.ai
Sign up

02487.HK

Cutia Therapeutics

HKSE · Healthcare · Biotechnology · CN

HKD 1.76
+0.57%
Ask drillr

  • Sep 2, 2026, 23:26 UTC

    Cutia's Biologics License Application for CU-20101 was accepted for review by China's National Medical Products Administration.

    Source:

  • Aug 31, 2026, 08:38 UTC

    Cutia Group reported interim results for the six months ended June 2026, with revenue of RMB 62.71 million, down 5.4% year-on-year, and a narrowed net loss of RMB 180 million compared to RMB 239 million in the prior-year period.

    Source: